iECURE
James M. Wilson serves as chief scientific advisor to iECURE. He is director of the Gene Therapy Program, Rose H. Weiss professor and director, Orphan Disease Center, professor of Medicine and Pediatrics in the Department of Medicine at the University of Pennsylvania. Dr. Wilson has made seminal contributions to the technology of gene transfer and has paved the way for translation of these technologies into the clinic. He has published over 600 papers and is named on more than 200 patents worldwide. He is the founder and president of a 501(c)3 called Health Through Fitness in Orphan Diseases. He earned his M.D. and Ph.D. at the University of Michigan and a BA in chemistry from Albion College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.